[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636278":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":7,"locations":8,"responsibleParty":28,"collaborators":7,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":36,"acronym":7,"eligibilityCriteria":37,"healthyVolunteers":34,"sex":38,"minAge":39,"maxAge":40,"enrollmentInfo":41,"targetDuration":7,"studyType":44,"phases":7,"briefSummary":45,"conditions":46,"keywords":7,"overallStatus":10,"whyStopped":7,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":57},{"fullName":5,"class":6},"Fondazione IRCCS Policlinico San Matteo di Pavia","OTHER",null,[9],{"facility":5,"status":10,"city":11,"state":12,"zip":13,"country":14,"countryCode":15,"cosmosGeoPoint":16,"geoPoint":21,"contacts":22},"RECRUITING","Pavia","Lombardy","27100","Italy","IT",{"type":17,"coordinates":18},"Point",[19,20],9.15917,45.19205,{"lat":20,"lon":19},[23],{"name":24,"role":25,"phone":26,"phoneExt":7,"email":27},"Teresa Rampino, MD","CONTACT","0382504504","t.rampino@smatteo.pv.it",{"type":29,"investigatorFullName":30,"investigatorTitle":31,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Teresa Rampino","Principal Investigator","100636278","prevalence-pathogenesis-and-prognosis-of-pulmonary-hypertension-in-dialysis-patients-100636278",false,"NCT07563608","Prevalence, Pathogenesis, and Prognosis of Pulmonary Hypertension in Dialysis Patients","Inclusion Criteria:\n\n* Patients aged between 18 and 75 years\n* Patients on stable extracorporeal hemodialysis for at least 6 months\n* Dialysis frequency of two or three times per week\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* WHO functional class IV\n* Presence of valvular or congenital heart disease\n* Acute infections within the month preceding the cardiological evaluation","ALL","18 Years","75 Years",{"count":42,"type":43},70,"ESTIMATED","OBSERVATIONAL","This prospective multicenter longitudinal study aims to investigate the prevalence, pathogenesis, and prognosis of pulmonary hypertension in patients with end-stage renal disease undergoing chronic hemodialysis. The research seeks to identify specific clinical factors and biomarkers like angiopoietin-2 that contribute to the development of this condition, while evaluating the prognostic value of right ventricular function measured via TAPSE. Participants undergo a standardized screening echocardiogram the day after their intermediate dialysis session to determine the probability of pulmonary hypertension. Those identified as high-risk receive further diagnostic confirmation through right heart catheterization, respiratory function tests, and lung scans to clarify the underlying etiology. The protocol also evaluates the hemodynamic impact of high-flow arteriovenous fistulas and volume overload on pulmonary pressures. Clinical follow-up is conducted at baseline and subsequently at 6, 12, and 24 months to monitor patient outcomes and standardize therapeutic management according to established European guidelines.",[47],"Pulmonary Hypertension","2026-04-29",{"date":50,"type":51},"2026-05-04","ACTUAL",{"date":53,"type":51},"2018-11-10",{"date":55,"type":43},"2026-09",{"name":5,"class":6},1]